| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Recombinant anti-IL-5 humanized monoclonal antibody (Shanghai CP Guojian) | 610; SSGJ-610 | Phase 3 Clinical | Sunshine GuoJian Pharmaceutical (Shanghai) Co Ltd | Asthma; Autoimmune Diseases | Details |
| SHR-1703 | SHR-1703 | Phase 3 Clinical | Jiangsu Hengrui Medicine Co Ltd | Asthma; Eosinophilic Asthma; Eosinophilic Granulomatosis With Polyangiitis | Details |
| RC-1416 | RC14/16; RC-1416 | Phase 2 Clinical | Nanjing RegeneCore Biotech Co Ltd | Asthma; Dermatitis, Atopic; Pulmonary Disease, Chronic Obstructive | Details |
| long-acting anti-IL-5 mAb (GSK) | Phase 1 Clinical | Glaxosmithkline Plc | Asthma | Details | |
| Mepolizumab biosimilar(Bio Thera Solutions) | BAT2606; BAT-2606 | Phase 1 Clinical | Bio-Thera Solutions Ltd | Asthma; Autoimmune Diseases; Nasal Polyps; Sinusitis | Details |
| Mepolizumab biosimilar (CTTQ Pharma) | TQC-3566; TQC3566 | Phase 1 Clinical | Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group | Asthma; Eosinophilic Granuloma; Eosinophilic Granulomatosis With Polyangiitis; Granulomatosis with Polyangiitis; Hypereosinophilic Syndrome; Lymphohistiocytosis, Hemophagocytic; Nasal Polyps; Sinusitis; Vasculitis | Details |
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Reslizumab | CEP-38072; SCH-5570; TRFK-5; SCH-55700; CDP-835; CTx-55700 | Approved | Teva Pharmaceutical Industries Ltd | Cinquil, Cinqair, Cinqaero | United States | Asthma | Teva Respiratory Llc | 2016-03-23 | Asthma; Bronchitis; Eosinophilic Esophagitis; Hypereosinophilic Syndrome; Loiasis; Pulmonary Eosinophilia | Details |
| Depemokimab | GSK-3511294; AQ82742999; GSK3511294; GSK-294; GSK294 | Approved | Glaxosmithkline Plc | 易适来, Exdensur | United Kingdom | Asthma; Sinusitis; Nasal Polyps | Glaxosmithkline Plc | 2025-12-15 | Asthma; Chronic rhinosinusitis with nasal polyps (CRSwNP); Eosinophilic Asthma; Eosinophilic Granuloma; Eosinophilic Granulomatosis With Polyangiitis; Hypereosinophilic Syndrome; Nasal Polyps; Pulmonary Disease, Chronic Obstructive; Sinusitis; Vasculitis | Details |
| Mepolizumab | SB-240563; 240563 | Approved | Glaxosmithkline Plc | Bosatria, Nucala, 美泊利珠单抗, 新可来 | United States | Asthma | Glaxosmithkline Llc | 2015-11-04 | Angioedema; Asthma; Bronchitis; Chronic rhinosinusitis with nasal polyps (CRSwNP); Chronic Urticaria; Dermatitis, Atopic; Eosinophilia; Eosinophilic Esophagitis; Eosinophilic Granulomatosis With Polyangiitis; Fasciitis; Granulomatosis with Polyangiitis; Hypereosinophilic Syndrome; Nasal Polyps; Pulmonary Disease, Chronic Obstructive; Sinusitis; Virus Diseases | Details |